BioCentury
ARTICLE | Clinical News

Thymalfasin: Phase III started

October 3, 2016 7:00 AM UTC

SciClone began a double-blind, placebo-controlled, Chinese Phase III trial to evaluate 1.6 mg subcutaneous Zadaxin twice daily for 7 days in 1,104 patients. SciClone’s Zadaxin is approved in >30 count...